Anda di halaman 1dari 21


discussions, stats, and author profiles for this publication at:

Prescribing contraceptives for women with


Article in Journal of Psychiatric Practice · July 2011

DOI: 10.1097/01.pra.0000400263.52913.dc


29 968

2 authors, including:

Mary V. Seeman
University of Toronto


Some of the authors of this publication are also working on these related projects:

Ethics View project

Need for solitude among individuals with schizophrenia View project

All content following this page was uploaded by Mary V. Seeman on 20 October 2017.

The user has requested enhancement of the downloaded file.


This  is  not  the  final  published  version  


Mary  V.  Seeman,  Ruth  Ross  Prescribing  contraceptives  for  women  with  schizophrenia.  
Journal  of  Psychiatric  Practice  2011;  17(4):258-­‐269.    
DOI:  10.1097/01.pra.0000400263.52913.dc    

Copyright ©2011 Lippincott Williams & Wilkins Inc.    



Although women with serious mental illness have high rates of lifetime sexual partners,
they infrequently use contraception. Consequently, the prevalence of unwanted pregnancies
and sexually transmitted infection is high in this population. The objective of this paper is
to help clinicians recommend appropriate contraception to women with schizophrenia. The
authors reviewed recent literature on the use of contraceptive methods by women with
schizophrenia treated with antipsychotic and adjunctive medications. Contraceptive
counseling to women and their partners is an important part of comprehensive care for
women with serious and persistent mental illness. Women with schizophrenia who smoke,
are overweight, or have diabetes, migraine, cardiovascular disease, or a family history of
breast cancer should be offered non-hormonal contraception. Women with more than one
sexual partner should be advised on barrier methods in addition to any other contraceptive
measures they are using. Clinicians should be alert for potential interactions among oral
hormonal contraceptives, smoking, and therapeutic drugs. Long-lasting contraceptive
methods, such as intrauterine devices, progesterone depot injections, or tubal ligation are
reasonable options for women having no wish to further expand their families.


Very few women with a diagnosis of schizophrenia ask their psychiatrists for contraceptive advice
and very few psychiatrists prescribe these medications. Yet unintended pregnancies in this
population have a major impact on the health of women and children, and on the cost of healthcare.
A recent study identified a number of barriers that may hinder clinicians from providing
contraceptive advice to their patients,1 including lack of contraceptive knowledge, insufficient
training, discomfort with the subject,2 and incorrect assumptions about pregnancy risk. For
example, psychiatrists may view patients with schizophrenia as asexual or too socially isolated for
interpersonal sex3 or they may wrongly believe that antipsychotic medication protects their patients
against pregnancy.4 They may also have negative perceptions of contraceptive methods or they may
prefer to wait for patients to introduce the topic. They may also see contraceptive counseling as
peripheral to the psychiatric role, delegating such discussions to the family physician, even though
many patients with schizophrenia do not see a family physician. It is also possible that discussing
contraception with psychiatric patients invokes distressing images of a bygone era when psychiatric
patients were sterilized against their will.5
Nevertheless, women who use mental health services have sexual and reproductive service
needs.6 Based on a 2009 review of 84 studies on reproductive health in women with serious mental
illness, Matevosyan concluded that the rate of lifetime sexual partners in this population is high
compared with other populations, that contraceptive usage is relatively low, and that there are high
rates of both unwanted pregnancies and sexually transmitted infections in this population.7 These
findings underscore the need for physicians to develop the skills needed to address contraceptive
and sexual safety issues with their patients. This selective review provides a brief overview of the
literature on this subject and presents clinical recommendations.


Prevalence of Contraceptive Use in Women with Mental Illness

Little is known about the frequency of contraception use in women diagnosed with mental disorders
and how these rates differ from those in the general population.8 In 2007, a Turkish study compared
family planning needs and contraceptive use in women with schizophrenia, bipolar disorder, and
unipolar depression (50 patients in each group) with a control group.9 Only 26.6% of the patients
with schizophrenia had had a gynecological examination in the preceding 3 years compared with
56% of the women in the control group. Of the patients with schizophrenia, only 40% had discussed
family planning issues with a partner---compared with 90% of controls.9 In 2009, Chilean
researchers conducted a study addressing the same issue in a sample of 255 women who were
mental health patients.10 Approximately half were parents and 60 had a diagnosis of schizophrenia.


Over 90% of the women (n = 233) reported having an active sexual life. Forty women had had their
tubes tied, mostly through their own choice, but, in 6 cases, a physician, partner, or family member
had made the decision. Of those using contraceptives (n = 35), most (n = 22) reported using oral
contraceptives, while the rest used condoms (n = 11) or an injectable contraceptive (n = 2).
However, and this speaks to inadequate counseling, almost 80% were judged to be using their
chosen method incorrectly. The rate of unplanned pregnancies in this study was high, partly, the
authors suggest, due to drug interactions between hormonal contraceptives and therapeutic drugs
that reduced the effectiveness of the contraceptives. These researchers concluded that the use of
contraceptive methods that require personal control is problematic for psychiatric patients and that
partners and/or family members need to be included in discussions about contraception.10
A systematic review of the published literature on sexually transmitted diseases (STDs) in
persons with chronic mental illness found many information gaps with respect to prevalence. 11
Although most patients with schizophrenia express concern about the risk of contracting infections
during sexual intercourse, they also report engaging in relatively unsafe sexual behavior and not
complying with contraceptive measures.12

Clinical and Social Implications of Unwanted Pregnancy and Sexually Transmitted Diseases
Unwanted pregnancy and infection, if not prevented, bring hardship not only to the woman herself
but also to her offspring. Unwanted pregnancy predicts schizophrenia-spectrum disorders in
offspring of mothers with psychosis.13 Maternal infection during pregnancy is also associated with
schizophrenia in offspring. 14,15

Reasons for Low Rates of Contraceptive Use in Women with Schizophrenia

Many women with schizophrenia do not use contraception because they mistakenly think they are
infertile when their periods become irregular or absent due to antipsychotic-induced
hyerprolactinemia. Myths such as these are common and need to be dispelled. It is important that
women with schizophrenia who are in their reproductive years and experience drug-induced
amenorrhea be educated that they have not undergone premature menopause and are still capable of
becoming pregnant. A recent study in women with anorexia nervosa, who similarly think that they
are infertile because they do not menstruate, found that 50% reported unplanned pregnancies and
24.2% reported having had an abortion.16
Some women put their trust in their partner using a condom or withdrawing at the right
time. Many women do not plan in advance on engaging in intercourse or they may become victims


of rape, since sexual assault is not rare in this population.17 Some patients, for various reasons, are
afraid to take contraceptive pills.

Many types of contraceptive methods are currently available. Psychiatrists need to be
knowledgeable about existing methods so that they can counsel their patients appropriately.18 The
following sections present a concise overview of the different methods in terms of their benefits,
drawbacks, and issues related to their use in women with schizophrenia.

Benefits. Sexual abstinence protects against both pregnancy and sexually transmitted disease.

Drawbacks. Abstinence provides no protection against unexpected contingencies.

Issues for women with schizophrenia. Abstinence is often the method that women with
schizophrenia opt for when they do not have a male partner and do not expect to have one. The
problem is that they may unexpectedly meet a partner or they may be the victim of non-consensual

Natural Family Planning

Natural methods of contraception include extra-genital sex, withdrawal (“coitus interruptus”),
rhythm, and checking cervical mucus or basal temperature. Such natural methods can be discussed
in an all women’s group, but it is preferable for partners to be present.

Benefits. Women may prefer to use natural methods and, when properly used, they are very
effective, a fact that physicians may underestimate.19 Natural birth control may be a good option for
women with committed partners and women whose religious faith does not permit the use of other

Drawbacks. In order for natural methods to be effective, women need to know how to use them
correctly.20 Also, in order to educate patients about these methods, physicians themselves need to
understand them.21


Issues for women with schizophrenia. The calculations involved may be too demanding for many
women, especially women with cognitive impairment such as is often present in schizophrenia.
Rhythm methods may not be effective in this population if antipsychotic drugs disrupt, as they often
do, the regularity of menstruation. These methods also offer no protection against STDs.

Female Barrier Methods

Female barrier methods include cervical caps, diaphragms, sponges, spermicides, and female
condoms. Cervical caps and diaphragms need to be fitted in a doctor’s office and replaced every 1
or 2 years. Both devices must be used with a foam, cream, jelly, or tablet spermicide. Contraceptive
sponges are impregnated with spermicide and do not need a prescription or a fitting. Package inserts
specify how long diaphragms, caps, and sponges can safely be kept in place. The female condom
comes in one size, does not need to be fitted, is prelubricated, and does not contain spermicide. It is
the only ‘woman-initiated’ device for prevention of both conception and STDs. Although studies
demonstrate high acceptability and effectiveness for the female condom, overall use in the United
States is low.22
Despite what some women believe, postcoital douching does not prevent conception and can
increase the risk of pelvic inflammatory disease and ectopic pregnancy.23

Benefits. Many women prefer female barrier methods since their use does not rely on the male

Drawbacks. Advance planning before intercourse is needed. The various female barrier methods
have a 15%--30% failure rate. Some barrier methods require fitting and maintenance and all of
these devices require some skill and experience to insert properly. Allergies to spermicides are not
rare. It has also recently been shown that spermicides may increase the risk of HIV infection,24
although new spermicides that can protect against STDs are being developed.25 Cost may also be an
issue with these methods.

Issues for women with schizophrenia. Women with schizophrenia may have difficulty ensuring
proper maintenance and use of barrier contraceptives, as well as lacking sufficient executive
functioning to plan for their use in advance.


Male Barrier Methods

Benefits. The male condom, especially when made out of latex and used correctly, provides
superior protection against both conception and infection. The male condom is the only proven
preventive tool against several sexually transmitted infections, especially HIV.26 Male latex
condoms are 97% effective if used correctly and consistently.

Drawbacks. The efficacy of condoms depends on the full co-operation of the male partner. Non-
latex condoms (for use when allergies develop to latex) have a greater failure rate than latex ones
for both infection and contraception.

Issues for women with schizophrenia. Women with schizophrenia have difficulty insisting that
their male partner wear a condom.

A permanently committed male partner can undergo vasectomy. Couple sessions are indicated to
discuss this option, which would be ideal for a monogamous woman with schizophrenia.

Combination Oral Contraceptives

The leading method of contraception in the United States during 2006--2008 was the oral
contraceptive pill, used by 10.7 million women, with female sterilization the second most common
method, used by 10.3 million women.27 Oral contraceptives contain either a combination of
estrogen and progestin or a progestin alone (see below for more information on progestin-only
methods), with the most popular option the combination estrogen/progesterone daily pill. Estrogen
usually comes in the form of ethinyl estradiol, although there is a recent pill that uses estradiol, the
body’s natural estrogen, in the hope that side effects will be fewer.28

Benefits. Oral birth control pills are 97%--99.9% effective if used correctly and consistently.
Hormonal contraceptive methods can stop menstruation for long periods, even indefinitely, a
feature that many women like. Remembering to take the pill daily is facilitated by the provision of
monthly packs.

Drawbacks. The pill does not protect against STDs, so the use of an accompanying barrier method
is required. Cost may be an issue if the woman has no insurance. Side effects, most of them caused
by the estrogen component of the pill, are concerns, especially in women who smoke, are


overweight, suffer from diabetes, or heart disease, or are at risk for breast cancer. Some women
taking low-dose oral contraceptive pills also complain of decreased libido and arousal because of
the decrease in testosterone, and some develop dyspareunia.29 A potentially serious side effect is
vascular thrombosis, the risk of which is increased by estrogen-containing pills. It is important to
note that oral contraceptives are not associated with an increased long-term risk of death. In fact, a
net benefit was found in a recent large cohort study from the United Kingdom.30 The balance of
risks and benefits, however, may vary globally, depending on patterns of oral contraception usage
and background risk of disease.30,31 To be safe, women 35 years of age and older should be assessed
for cardiovascular risk factors including hypertension, smoking, diabetes, nephropathy, and other
vascular diseases, including migraines, prior to use of oral contraceptives.32

Issues for women with schizophrenia. For women with schizophrenia, taking a daily contraceptive
may reinforce the daily routine of taking their antipsychotic medication and may thus prove helpful
for treatment adherence, although there is no evidence of this. At the same time, remembering to
take the pill daily can be a challenge for women who do not have a daily routine.
Hormones can also interact with therapeutic medications to reduce the effectiveness either
of the contraceptive or the therapeutic agent (see discussion of Drug Interactions later in this
Physicians often underestimate the impact of contraceptive methods on sexual function,
which is especially problematic for women with schizophrenia whose libido is already low because
of the medications they are taking.33
Comorbid conditions that can present problems for use of the pill, such as smoking,
obesity, diabetes, and other cardiovascular risk factors, are not rare in women with schizophrenia.
The freedom of sexual activity without pregnancy is the main advantage, but there is also potential
benefit of estrogen for schizophrenia symptoms themselves. Accumulating evidence from clinical
data and basic and experimental research, as well as epidemiologic studies, suggests that estrogens
exert therapeutic effects in schizophrenia. The onset of schizophrenia in women is about 5 years
later than in males and this has been attributed to the protective effect of estrogen. Women are
especially vulnerable to relapse of existing illness during the postpartum period when estrogen
levels have decreased, and at menopause. Severity of symptoms has also been observed to fluctuate
with menstrual cycle phases, increasing during low-estrogen phases. Intervention studies using
estrogen as a therapeutic agent have provided further support for the hypothesis that estrogen
modulates the expression of psychotic symptoms. 34—36 This, of course, must be balanced against the
known side effects and risks of hormones. The risk of vascular thrombosis is increased both by


estrogen-containing pills and by antipsychotic medication. Estrogen use is usually considered a risk
for venous thrombosis, whereas smoking, hypertension, diabetes, the metabolic syndrome, and
hyperlipidemia (all of which can be aggravated by antipsychotics) are thought to be risks for arterial
thrombosis. A number of recent studies have recently challenged this dichotomy, and it is now
recognized that venous and arterial thromboses share risk factors and both can lead to
cardiovascular stroke.37--39
Physiologic and pharmacologic interactions between obesity and contraceptive steroids can
occur,40 which is a particular concern for women with schizophrenia, given the weight-inducing
effects of some antipsychotic medications. Obesity may result in lower blood levels of steroid
contraceptives, but the effect is thought to be relatively small. Of three studies that examined body
mass index and pregnancy rates in women taking combination oral contraceptives, only one found a
greater risk of pregnancy in overweight and obese women.41,42

Progesterone-only Contraceptives
Progesterone-only pills and long-acting progesterone injections (medroxyprogesterone acetate or
Depo-Provera) are also available.43 Depo-Provera is given every 3 months as a 150 mg
intramuscular injection.

Benefits. Depo-Provera is a very effective contraceptive, with a failure rate of less than 1%. It has
no appreciable effects on blood pressure, cholesterol, triglycerides, or thrombosis risk, an important
advantage. No significant adverse effects on growth and development have been found in children
exposed to DepoProvera. No major delays in return to fertility after stopping the injection have been
observed. The injections are not associated with any increased risk of ovarian, liver, or cervical
cancer, while the risk of endometrial cancer may be reduced.

Drawbacks. To be fully effective, the progesterone-only pill has to be taken within the same 3 hours
each day. Progesterone-only methods all cause some degree of menstrual disturbance (e.g., break-
through bleeding). They can also infrequently decrease libido and cause dyspareunia.33
DepoProvera njections are associated with weight gain, can increases truncal fat deposition, and
have been found to lowers glucose tolerance in women with diabetes.44 The injections are also
temporarily irreversible during their 3 month duration, which is a concern if problematic side effects
develop. An increased risk of breast cancer has been observed, which could be due to higher rates of
detection. Bone mineral density is decreased and there is a slightly increased risk of fractures,45
which can be decreased by not smoking and increasing calcium intake.46


Issues for women with schizophrenia. The need to take the progesterone pill during the same time
period each day places considerable strain on women who lead irregular lives. Although they may
not enjoy needles, for women with schizophrenia who have difficulty managing other birth control
methods, an injection every 12 weeks may be ideal (but it does not protect them from sexually
transmitted disease).

Other Hormonal Formulations

Hormones can also be delivered by skin patch or subdermal implant, vaginal ring or transdermal gel
or spray. The skin patch is applied weekly for 3 weeks with 1 week off. The implant is a rod
inserted under the skin by a physician that can stay in place for up to three years. Implant removal is
technically more difficult and time-consuming than insertion. These methods are uncomfortable for
some women and they do not, of course, protect against STDs. Patches, rings and subdermal
implants are 97%--99% effective in preventing pregnancy. The hormones in patches, rings, and
implants bypass the liver and therefore are not subject to drug interactions via metabolism by liver

Issues for women with schizophrenia. Some women will prefer long-lasting methods that do not
require coming in for injections every 12 weeks although cost will be a problem in this population.

 Intrauterine  Devices  
Intrauterine devices (IUDs) are placed within the uterus by a physician. The best-known IUDs
contain copper, but progestin-impregnated IUDs (e.g., levonorgestrel IUD) are also available.
Current evidence suggests that hormonally impregnated IUDs are somewhat more effective in
preventing pregnancy than copper IUDs, although it depends on the specific devices being
compared. Continuation of use is similar among hormonal and non-hormonal IUDs.47

Benefits. Like hormones in patches, rings, and implants, hormones in IUDs bypass the liver and
therefore are not subject to drug interactions via metabolism by liver enzymes. IUDs have similar
contraceptive efficacy as combined oral contraceptives when those are used correctly, but are more
effective than oral contraception that is incorrectly used. Unfortunately, a recent study suggested
that women receive comparatively little information about IUDs.48 Problems such as difficult
insertion, pain, bleeding, and syncope are reported in less than 1.5% of cases. A copper IUD is a


first-line contraceptive method for women with a history of deep venous thrombosis, pulmonary
embolism, or heart disease. It provides contraception for up to 10 years, with annual pregnancy
rates of less than 1 per 100 woman-years.49

Drawbacks. IUDs can be accidentally expelled from the body, sometimes without the person
realizing it. This has been reported to occur in about 5% to 10% of cases within 5 years of insertion,
and expulsion recurs in about 30% of cases. Condoms have to be used as well as the IUD to prevent
infection with sexual transmitted diseases. Although the rare intrauterine pregnancies that occur in
women using an IUD generally end in miscarriage, approximately 1 in 20 of these pregnancies is
ectopic. Uterine perforation during insertion is rare, but does occur in 0.6 to 16 per 1000 insertions
regardless of type of IUD. The risk of perforation is higher when the IUD is inserted less than 4 to 6
weeks after delivery or abortion. During the first 3 months after insertion, the risk of pelvic
infection is slightly higher than in the general population, with approximately 6 pelvic infections
per 1000 woman-years of IUD use expected. Menstrual bleeding is often heavier in women with
copper IUDs than in women who do not use IUDs, and may be accompanied by pain. The
levonorgestrel IUD tends to reduce menstrual blood loss but can cause irregular bleeding;
amenorrhoea occurs in 35% of women after 2 years of use. The levonorgestrel IUD may also have
adverse effects such as headache, acne, breast tension, and functional ovarian cysts.

Issues for women with schizophrenia. IUDs have been recommended as the most suitable
contraceptive system for women with chronic illness because they are long-lasting and require little
attention. This is especially true when the woman does not intend to become pregnant in the near
future and finds planning and remembering to take daily pills difficult.50 A chart review comparing
uses of IUDs and Depo-Provera in high risk women found that the women with IUDs were more
likely to report side effects but were less likely to discontinue use.51

Emergency Contraception
Because sexual activity is often unplanned and unpredictable among women with schizophrenia,
emergency contraception (EC) is a necessary back up. Concerns about the mechanisms of action of
EC methods are a major barrier to the widespread acceptance and use of EC. Women need to be
educated that EC pills are contraceptives, not aborticants. EC is available without a prescription and
several forms are now available.52 EC is safe and reduces the risk of pregnancy by 75%--89%. The
most widely used EC is levonorgestrel (LNG) in a single dose of 1.5 mg taken within 120 hours of
unprotected intercourse. LNG-EC delays or inhibits ovulation but has no effect once luteinizing
hormone has been released.53 It is possible to obtain the same effect by taking several regular


combined oral contraceptive pills, an off-label use approved by the U.S. Food and Drug
administration. Ulipristal acetate was approved as EC in the United States in 2010. It also works for
up to 120 hours after intercourse.54 The copper intrauterine device (IUD) is also highly effective as
an emergency contraceptive but requires insertion by a skilled healthcare provider. If a woman is
already pregnant, EC will not harm the fetus. Temporary side effects include nausea or vomiting.
Less common side effects are headache, breast tenderness, dizziness, fluid retention, mood changes,
or abdominal cramps. These side effects rarely last more than 2 days. The next menstruation can
come later than expected.

Abortion Pills
Administration of mifepristone followed by the prostaglandin, misoprostol, has been used
successfully in the medical termination of pregnancy for over 25 years, and the method is registered
in 35 countries. However, mifepristone is not approved for emergency contraceptive use in the
United States because understanding of its mechanism of action is incomplete. Unlike other EC,
mifepristone can terminate established pregnancies.55

Surgical Methods
Surgical contraception, therapeutic abortion, and sterilization are problematic methods because of
religious, moral, and ethical concerns. Nevertheless, many countries still advocate voluntary
sterilization for women with serious mental illness. The important issue is to ensure that the woman
making the decision is fully informed of consequences and is fully competent to make the decision.
Surrogate consent is sometimes necessary but should be avoided if possible. Therapeutic abortion is
not available in many jurisdictions and may be contrary to the woman’s personal convictions and
those of her healthcare provider or institution; in these latter cases, second opinions should be

Summary of Effectiveness
Table 1 summarizes the main advantages and disadvantages of the different contraceptive methods
for women with schizophrenia. The hierarchy of contraceptive effectiveness in descending order
1. Female sterilization and long-acting hormonal contraceptives (IUDs and implants)
2. Larger copper IUDs
3. Smaller copper IUDs and short-acting hormonal contraceptives (injectables, oral
contraceptives, patch, vaginal ring)


4. Barrier and natural methods.


Oral contraceptives can have clinically significant interactions with many drugs.57 Clinicians need
to consider the following critical questions:

· Is the level of the concomitant drug increased sufficiently so that side effects will develop
or is it decreased sufficiently to undermine its efficacy?
· Is the level of the contraceptive reduced sufficiently so that it will no longer prevent

Anti-epileptic agents. The most notable interactions involve antiepileptic drugs (AEDs), which are
sometimes used as adjunctive agents in the treatment of schizophrenia or to prevent side effects of
antipsychotics.58 Combined oral contraceptives lower the levels of both valproate and lamotrigine
making them less effective.59,60 On the other hand, many AEDs (phenobarital, phenytoin,
carbamezapine, felbamate, oxcarbazepine and topiramate induce cytochrome P450 3A4, leading to
enhanced metabolism of either or both the estrogenic and progestogenic components of oral
contraceptives, thereby reducing their efficacy in preventing pregnancy.61 Benzodiazepines,
gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, zonisamide and ethosuximide are
not associated with clinically significant pharmacokinetic interactions.62,63

Antipsychotic medications. When combination oral contraceptives are taken together with the
antipsychotic drug clozapine, which is metabolized by 3A4, 1A2, and 2C19, there is a significant
increase in clozapine blood levels, with levels almost tripling. This can result in important side
effects, including hypotension, sedation, tremor, and nausea.64 The same effect occurs when
combination oral contraceptives are combined with the antipsychotic chlorpromazine.65,66
Discontinuing contraceptives during the course of treatment with one of these antipsychotics
decreases clozapine or chlorpromazine blood levels, necessitating a compensatory increase in the
antipsychotic dose in order to maintain a therapeutic blood level. While the antipsychotic
ziprasidone is also metabolized by CYP 3A4, it does not appear to significantly inhibit this enzyme
at clinically relevant concentrations,67 so that dose adjustments are only needed for clozapine and
chlorpromazine when taken with oral contraceptives.

Many women with schizophrenia smoke, and pharmacodynamic interactions between nicotine and


estrogen can produce serious adverse cardiovascular effects.68 The use of hormonal contraceptives
of any kind in women who are 35 years of age or older and smoke 15 or more cigarettes daily is
contraindicated. It has been proposed that smoking causes “sticky fibrin” to develop, which leads to
thrombotic events.69 Although smoking does not reduce the efficacy of oral contraceptives, the level
of many antipsychotics is reduced by smoking. When a woman stops smoking, the blood levels of
these antipsychotics rise. Contraceptives can also cause levels of some antipsychotics (clozapine
and chlorpromazine) to rise, which can lead to an increase of side effects.


Knowledge of contraceptive methods is relatively limited among women with schizophrenia, so that
it is important that these women have access to a skilled, knowledgeable counselor.70 In addition to
receiving education concerning contraception and prevention of STDs, barriers to contraceptive
access must be removed.71 Patients also need to be motivated to adhere to their chosen regimens.
Virtually no experimental or observational literature reliably answers questions about the
effectiveness of counseling in reducing unwanted pregnancy,72 but most studies conclude that there
is substantial room for quality improvement in its provision.73 Research into effective contraception
counseling is therefore needed.74 Some of the reproductive health counseling approaches that
clinicians report using (authoritarian, parental, fear-instilling) are not consistent with current
theories of behavioral change or the goal of patient-centered counseling.75,76 Motivational
interviewing, a method that identifies discrepancies between a woman’s goals and her behaviors
and supports her own wishes, has been successful in other domains and is being tried for pregnancy
From an ethical viewpoint, modern gender-sensitive mental health services must support
patients with mental disorders should they decide to become pregnant.78 Contraceptives can only be
prescribed with a woman’s full understanding of what they are for, how they are to be used,
contraindications to their use, and expected side effects. Impaired decision-making on the part of
the patient needs to be assessed and treated, so that she can fully participate in family planning
decisions.79--81 Programs designed to enhance sexual health decision-making and behavioral change
in this population are feasible and need to be implemented.82

Psychiatrists need to address contraception during regular psychiatric visits with all seriously ill
women in their reproductive years. Partners should also be invited to join these discussion.


Contraceptive options can be revisited periodically in individual, family, and group settings. Non-
hormonal contraceptive measures should be recommended for women who smoke, who are
overweight or have diabetes, migraines, or cardiovascular disease, or who have a family history of
breast cancer. To prevent against infection with STDs, women with more than one sexual partner
should be advised to use barrier methods in addition to any other contraceptive measures they are
using. Clinicians should be alert for interactions among contraceptives, smoking, and therapeutic
drugs, especially when starting or stopping oral hormonal contraceptives. Long-lasting
contraceptive methods, such as IUDs, progesterone depot injections, or tubal ligation, are
reasonable options for women having no wish to further expand their families. Finally,
contraceptive counseling is an important part of comprehensive care for serious and persistent
mental illness.



1. Akers AY, Gold MA, Borrero S, et al. Structured contraceptive counseling—A

randomized controlled trial. J Women's Health 2010;19:1163--70.
2. Haboubi NH, Lincoln N. Views of health professionals on discussing sexual issues
with patients. Disabil Rehabil 2003;25:291--6.
3. Wright ER, Wright DE, Perry BL, et al. Stigma and the sexual isolation of people
with serious mental illness. Social Problems 2007;54:78--98.
4. Currier GW, Simpson GM. Psychopharmacology: Antipsychotic medications and
fertility. Psychiatr Serv 1998;49:175--6.
5. Torrey EF, Yolken RH. Psychiatric genocide: Nazi attempts to eradicate
schizophrenia. Schizophr Bull 2010;36:26--32.
6. Abel K, Rees S. Reproductive and sexual health of women service users: What’s the
fuss? Adv Psychiatr Treat 2010;16:279--80.
7. Matevosyan NR. Reproductive health in women with serious mental illnesses: A
review. Sexuality Disab 2009;27:109--18.
8. Burt VK, Hendrick VC. Gender issues in the treatment of mental illness. Focus
9. Pehlivanoglu K, Tanriover O, Tomruk N, et al. Family planning needs and
contraceptive use in female psychiatric outpatients. Turkish J Fam Med Primary
Care 2007;1:32--5.
10. Gomes Guedes T, Ferreira Moura ER, De Almeida PC. Particularities of family
planning in women with mental disorders. Revista Latino-Americana de
Enfermagem 2009;17:639--44.
11. Nogueira Campos L, Guimarães MDC, Andrade Carmo R, et al. HIV, syphilis, and
hepatitis B and C prevalence among patients with mental illness: A review of the
literature. Cad. Saúde Pública 2008;24:S07--20.
12. Raja M, Azzoni A. Sexual behavior and sexual problems among patients with
severe chronic psychoses. Eur Psychiatry 2003;18:70--6.
13. McNeil TF, Schubert EW, Cantor-Graae E, et al. Unwanted pregnancy as a risk
factor for offspring schizophrenia-spectrum and affective disorders in adulthood: A
prospective high-risk study. Psychol Med 2009;39:957--65.
14. Ellman LM, Deicken RF, Vinogradov S, et al. Structural brain alterations in
schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8.
Schizophr Res 2010;121:46--54.
15. Bukaab SL, Cannon TD, Torrey EF, et al. Maternal exposure to herpes simplex
virus and risk of psychosis among adult offspring. Biol Psychiatry 2008;63:809--15.
16. Bulik CM, Hoffman ER, Von Holle A, et al. Unplanned pregnancy in women with
anorexia nervosa. Obstet Gynecol 2010;116:1136--40.
17. Choe JY, Teplin LA, Abram KM. Perpetration of violence, violent victimization,
and severe mental illness: Balancing public health concerns. Psychiatr Serv
18. Dehlendorf C, Levy K, Ruskin R, et al. Health care providers’ knowledge about
contraceptive evidence: A barrier to quality family planning care? Contraception


19. The European Natural Family Planning Study Groups. European multicenter study
of natural family planning (1989-1995): Efficacy and drop-out. Adv Contracept
20. Tommaselli GA, Guida M, Palomba S, et al. The importance of user compliance on
the effectiveness of natural family planning programs. Gynecol Endocrinol
21. Choi J, Chan S, Wiebe E. Natural family planning: Physicians' knowledge,
attitudes, and practice. J Obstet Gynaecol Can 2010;32:673--8.
22. Witte SS, Stefano K, Hawkins C. Can medicaid reimbursement help give female
condoms a second chance in the United States? Am J Public Health 2010;100:1835-
23. Martino JL, Vermund SH. Vaginal douching: Evidence for risks or benefits to
women’s health. Epidemiol Rev 2002;24:109--24.
24. Batár I. State-of-the-art of non-hormonal methods of contraception: II. Chemical
barrier contraceptives. Eur J Contracept Reprod Health Care 2010;15:89--95.
25. Cagnacci A, Ferrari S. Evolution and future of contraception. Minerva Ginecol
26. Batár I, Sivin I. State-of-the-art of non-hormonal methods of contraception: I.
Mechanical barrier contraception. Eur J Contracept Reprod Health Care
27. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital
Health Stat 23 2010;29:1--44.
28. Anonymous. What role for Qlaira in contraception? Drug Ther Bull 2010;48:102--5.
29. Lee M, Morgan M, Rapkin A. Clitoral and vulvar vestibular sensation in women
taking 20 mcg ethinyl estradiol combined oral contraceptives: A preliminary study.
J Sex Med 2010 Oct 18. [Epub ahead of print]
30. Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill
users: Cohort evidence from Royal College of General Practitioners' Oral
Contraception Study. BMJ 2010;11;340:c927.
31. Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study
with special reference to oral contraceptive use. Contraception 2010;82:22--9.
32. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular
disease. J Am Coll Cardiol 2009;53:22--31.
33. Shah MB, Hoffstetter S. Contraception and sexuality. Minerva Ginecol 2010;
34. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: A
potential new treatment approach. Arch Gen Psychiatry 2008;65:955--60.
35. Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential
therapeutic implications—review. Arch Womens Ment Health 2002;5:111–8.
36. Riecher-Rössler A, de Geyter C. The forthcoming role of treatment with oestrogens
in mental health. Swiss Med Wkly 2007;137: 565--72.
37. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: Basic
pathophysiology. Crit Care Med 2010;38:S3--9.
38. Jönsson AK, Horváth-Puhó E, Hägg S, et al. Antipsychotics and risk of venous
thromboembolism: A population-based case-control study. Clin Epidemiol
39. Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous


thromboembolism: Nested case-control study. BMJ 2010;341:c4245

40. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of
contraceptive steroids in obese women: A review. Contraception 2010;82:314—23.
41. Skouby SO. Hormonal contraception in obesity, the metabolic syndrome, and
diabetes. Ann N Y Acad Sci 2010;1205:240--4.
42. Anonymous. Hormonal contraceptives for contraception in overweight or obese
women. Obstet Gynecol 2010;116:1206--7.
43. Sitruk-Ware R, Nath A. The use of newer progestins for contraception.
Contraception 2010;82:410--7.
44. Verhaeghe J. Hormonal contraception in women with the metabolic syndrome: A
narrative review. Eur J Contracept Reprod Health Care 2010;15:305--13.
45. Meier C, Brauchli YB, Jick SS, et al. Use of depot medroxyprogesterone acetate
and fracture risk. J Clin Endocrinol Metab 2010;95:4909--16.
46. Rahman M, Berenson AB. Predictors of higher bone mineral density loss and use of
depot medroxyprogesterone acetate. Obstet Gynecol 2010;115:35--40.
47. French R, Van Vliet H, Cowan F, et al. Hormonally impregnated intrauterine
systems (IUSs) versus other forms of reversible contraceptives as effective methods
of preventing pregnancy. Cochrane Database Syst Rev 2004;3:CD001776
48. Rubin SE, Winrob I. Urban female family medicine patients' perceptions about
intrauterine contraception. J Womens Health (Larchmt) 2010;19:735--40.
49. Anonymous. Intrauterine devices: An effective alternative to oral hormonal
contraception. Prescrire Int. 2009;18:125--30.
50. Saarikoski S. Chronic illness and contraception. Duodecim 1987;103:593--7.
51. Cropsey KL, Matthews C, Campbel S, et al. Long-term, reversible contraception
use among high-risk women treated in a university-based gynecology clinic:
Comparison between IUD and depo-provera. J Womens Health (Larchmt)
52. Cremer M, Masch R. Emergency contraception: Past, present and future. Minerva
Ginecol 2010;62:361--71.
53. Gemzell-Danielsson K. Mechanism of action of emergency contraception.
Contraception 2010;82:404--9.
54. Russo JA, Creinin MD. Ulipristal acetate for emergency contraception. Drugs
Today (Barc) 2010;46:655--60.
55. Spitz IM. Mifepristone: Where do we come from and where are we going? Clinical
development over a quarter of a century. Contraception 2010;82:442--52.
56. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A
review of the literature. Eur J Contracept Reprod Health Care 2010;15:4--16.
57. Banck DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives.
Clin Pharmacokin 1990;18:472–84.
58. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug
interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31:198--214.
59. Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation
with menstrual cycle phase and oral contraceptive use. Neurology 2009;72:911--4.
60. Wegner I, Edelbroek PM, Bulk S, et al. Lamotrigine kinetics within the menstrual
cycle, after menopause, and with oral contraceptives. Neurology 2009;73:1388--93.
61. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate.
Clin Pharmacokinet 2004;43:763--80.


62. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new
second- and third-generation antiepileptic drugs. Expert Rev Neurother
63. Reddy DS. Clinical pharmacokinetic interactions between antiepileptic drugs and
hormonal contraceptives. Expert Rev Clin Pharmacol 2010;3:183--92.
6 4. Gabbay V, O'Dowd MA, Mamamtavrishvili M, et al. Clozapine and oral
contraceptives: A possible drug interaction. J Clin Psychopharmacol 2002;22:621--
65. Brown D, Goosen TC, Chetty M, et al. Effect of oral contraceptives on the transport
of chlorpromazine across the CACO-2 intestinal epithelial cell line. Eur J Pharm
Biopharm 2003;56:159--65.
66. Chetty M, Miller R. Oral contraceptives increase the plasma concentrations of
chlorpromazine. Ther Drug Monit 2001;23:556--8.
67. Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ. Ziprasidone and the
pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 2000;49:
68. Kroop LA. Drug interactions with smoking. Am J Health-Syst Pharm 2007;
69. Pretorius E, Oberholzer HM, van der Spuy WJ, et al. Smoking and coagulation: The
sticky fibrin phenomenon. Ultrastruct Pathol 2010;34:236--9.
70. Harper CC, Brown BA, Foster-Rosales A, et al. Hormonal contraceptive method
choice among young, low-income women: How important is the provider? Patient
Educ Couns 2010;81:349—54.
71. Sawhill I, Thomas A, Monea E. An ounce of prevention: Policy prescriptions to
reduce the prevalence of fragile families. Future Child 2010;20:133--55.
72. Moos MK, Bartholomew NE, Lohr KN. Counseling in the clinical setting to prevent
unintended pregnancy: An evidence-based research agenda. Contraception
73. Weisman CS, Maccannon DS, Henderson JT, et al. Contraceptive counseling in
managed care: Preventing unintended pregnancy in adults. Womens Health Issues
74. Hock-Long L, Whittaker P.G, Herceg-Baron R. Family planning service delivery
research: A call to focus on the dynamics of contraceptive use. Perspect Sex Reprod
Health 2010;42:10–11.
75. Henderson JT, Raine T, Schalet A, et al. “I Wouldn't Be this Firm if I Didn't Care":
Preventive clinical counseling for reproductive health. Patient Educ Couns
76. Lopez LM, Tolley EE, Grimes DA, et al. Theory-based strategies for improving
contraceptive use: A systematic review. Contraception 2009;79:411–7.
77. Petersen R, Payne P, Albright J, et al. Applying motivational interviewing to
contraceptive counseling: ESP for clinicians. Contraception 2004;69:213--7.
78. Kulkarni J. Special issues in managing long-term mental illness in women. Int Rev
Psychiatry 2010;22:183--90.
79. Coverdale JH, Bayer TL, McCullough LB, et al. Respecting the autonomy of
chronic mentally ill women in decisions about contraception. Hosp Community
Psychiatry 1993;44:671--4.


80. Coverdale JH, Turbott S, Roberts H. Family planning needs and STD risk
behaviours of female psychiatric outpatients. Br J Psychiatry 1997;171:69--72.
81. Miller LJ. Sexuality, reproduction, and family planning in women with
schizophrenia. Schizophr Bull 1997;23:623--35.
82. Lloyd C, Williams PL, King R. A sexual health programme implemented in a
psychiatric inpatient unit. NZ J Occupational Therapy 2005;52:26--32.


View publication stats